Mirum Pharmaceuticals (MIRM) Net Income (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Net Income of -$790.2 million for Q1 2026, down 5283.63% year-over-year from $15.2 million in Q1 2025, and down 13689.79% quarter-over-quarter from -$5.7 million in Q4 2025.
Analysis
Mirum Pharmaceuticals (MIRM) Net Income (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Net Income history runs 8 years deep, the most recent figure standing at -$790.2 million for Q1 2026.
- In Q1 2026, Net Income fell 5283.63% year-over-year to -$790.2 million; the TTM figure through Mar 2026 stood at -$798.8 million (down 932.9% YoY), while the FY2025 annual figure was -$23.4 million, up 73.43% from the prior year.
- Net Income for Q1 2026 stood at -$790.2 million, down from -$5.7 million in the prior quarter.
- The five-year high for Net Income was $2.9 million in Q3 2025, with the low at -$790.2 million in Q1 2026.
- The 5-year median for Net Income is -$25.3 million (2024), against an average of -$70.6 million.
- The sharpest annual moves came in 2025 and 2026: Net Income soared 120.41% in 2025, then plunged 5283.63% in 2026.
- Mirum Pharmaceuticals' Net Income stood at -$36.4 million in 2022, then grew by 2.12% to -$35.7 million in 2023, then jumped by 33.28% to -$23.8 million in 2024, then surged by 75.91% to -$5.7 million in 2025, then tumbled by 13689.79% to -$790.2 million in 2026.
- Business Quant data shows MIRM's Net Income at -$790.2 million in Q1 2026, -$5.7 million in Q4 2025, and $2.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Mirum Pharmaceuticals | 6.40 Bn | 5.96 Bn | 145.90 Mn | -67.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -67.23 Mn |
| Mar 31, 2026 | -790.16 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -14.68 Mn |
| Dec 31, 2024 | -23.79 Mn |
| Sep 30, 2024 | -14.24 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -35.66 Mn |
| Sep 30, 2023 | -23.59 Mn |
| Jun 30, 2023 | -74.04 Mn |
| Mar 31, 2023 | -30.13 Mn |
| Dec 31, 2022 | -36.43 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | 57.28 Mn |
| Sep 30, 2021 | -47.11 Mn |